drugset / Trial / NCT04108208

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

NCT04108208

Phase 4 Active not recruiting 75 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).

Timeline

Start
2019-12-17
Primary completion
2023-06-01
Completion
2026-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Apalutamide Small molecule 240 mg Oral

Indications